Phase I/II Study of SENL103 for Relapsed or Refractory Multiple Myeloma: A Multicenter, Open-Label, Single-Arm Trial.

NCT07421856 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma in Relapse
Multiple Myeloma Refractory

Interventions

BIOLOGICAL: Autologous BCMA-targeting CAR T cells

Sponsor

Hebei Senlang Biotechnology Inc., Ltd.

Collaborators

[object Object]
[object Object]